Shanghai Sonyt Biotechnology Co., Ltd. yog ib qho ntawm cov ua lag luam thiab cov muag khoom ntawm survodutide tfa hauv Suav teb, kuj txhawb kev pabcuam kev cai. Txais tos rau kev lag luam wholesale bulk zoo survodutide tfa los ntawm peb lub hoobkas. Tiv tauj peb kom paub meej ntxiv.
↵
| Khoom npe | Survodutide TFA |
| Kev piav qhia | Survodutide yog ib tug tshiab - tiam ntev - ua yeeb yam dual agonist ntawm GLP-1 receptor thiab glucagon receptor. Nws ua kom muaj txiaj ntsig zoo rau ob qho tib si metabolic receptors: txhawb cov piam thaj -nyob ntawm cov tshuaj insulin tso tawm, inhibits plab hnyuv thiab txo cov zaub mov noj ntawm GLP-1 txoj hauv kev; nce basal zog siv thiab txhawb lipolysis ntawm txoj kev glucagon, exerting ntau yam metabolic cov txiaj ntsig ntawm cov piam thaj txo qis, poob phaus thiab tswj lipid. Hloov kho nrog fatty acid side chains, nws tau zoo heev txhim kho peptidase tsis kam thiab ua kom ntev hauv vivo ib nrab-lub neej, txhawb kev ncua sijhawm ntev. Hauv cov tsiaj rog rog thiab hom 2 mob ntshav qab zib hom 2, nws koob tshuaj-raws li txo lub cev hnyav, txhim kho glycemic tswj thiab insulin rhiab heev. Nws yog cov cuab yeej tseem ceeb peptide rau kev tshawb fawb txog kev rog rog, ntshav qab zib hom 2, tsis haus dej cawv steatohepatitis thiab metabolic peptide tshuaj txhim kho. |
| Peptide Purity (HPLC, %) | 95% / 98% / 99% |
| Dawb puag molecular hnyav (Da) | ~ 4180, siab dua rau TFA ntsev daim ntawv |
| Hom qauv | Linear modified peptide, fatty acid side chain modification, trifluoroacetate ntsev |
Product Basic Information Table
| Khoom Lub Npe Lus Askiv | Product Abbreviation / Alias | Function Tags (comma-sib cais) | Core Structure | Molecular Formula | Exact Mass (Da) | Qhov nruab nrab MW (Da) | Daim ntawv ntsev | Ntev (aa) |
| Survodutide TFA | IB 456906 TFA | GLP-1R/GCGR dual receptor agonist, ua haujlwm ntev cov piam thaj txo qis & poob phaus, kev siv hluav taws xob nce siab, kev tswj cov metabolism | Ntev- ua yeeb yam hloov kho peptide ua kom zoo raws li cov pob txha caj qaum glucagon; fatty acid side chain modifications prolongs in vivo ib nrab -lub neej, balancedly activates GLP-1 thiab glucagon receptors | Dawb puag: C₁₈₉H₂₉₃N₄₅O₅₈ | 4178.13 | 4180.6 | Trifluoroacetate (TFA) | 39 |
Physicochemical Solubility & Cia Parameters
| Khoom Code | Qhov tshwm sim | Ntev - Lub Sij Hawm Cia | Luv - Lub Sij Hawm Cia | Kev daws teeb meem | Khoom hmoov ruaj khov |
| PEB-SUR001 | hmoov dawb | Khaws ntawm -20 degree, kaw, qhuav thiab tiv thaiv los ntawm lub teeb, hauv qab cua nitrogen. Aliquot kom tsis txhob rov qab khov-thaw mus. | ruaj khov rau 2 xyoos ntawm 2-8℃nyob rau hauv kaw qhuav; ruaj khov rau luv luv -lub sij hawm shipping ntawm ambient kub, haum rau chav tsev kub logistics. | ruaj khov rau 7 hnub ntawm 4 degree. Solubility: ~ 100 mg / mL hauv DMSO (yuav tsum tau sonication); me ntsis soluble hauv dej ntshiab. Npaj aqueous tov los ntawm serial dilution los ntawm DMSO Tshuag. Fatty acid sab saw nyhav ua rau peptide aggregation; zam rov qab khov -thaw. | ruaj khov rau 3 xyoos ntawm -20℃thiab 2 xyoos ntawm 4 degree, qhuav thiab tiv thaiv los ntawm lub teeb. |
Functional Description
| Khoom Code | Frontend Short Summary (rau cov npe tshawb nrhiav) | Cov lus piav qhia txog kev ua haujlwm lom neeg lom neeg | Cov cheeb tsam tshawb fawb (comma- cais) | Lub Hom Phiaj / Txoj Kev |
| PEB-SUR001 | Ntev - ua yeeb yam GLP-1 / glucagon dual receptor agonist nrog synergistic qabzib txo qis, poob phaus thiab siv zog ntxiv | Survodutide yog ib tug tshiab - tiam ntev - ua yeeb yam dual agonist ntawm GLP-1 receptor thiab glucagon receptor. Nws ua kom muaj txiaj ntsig zoo rau ob qho tib si metabolic receptors thiab synergistically drives downstream cAMP signaling txoj kev: txhawb cov piam thaj -nyob ntawm cov insulin secretion, inhibits plab hnyuv ntxwm thiab txo cov khoom noj ntawm GLP-1 txoj kev; tsub kom basal zog siv, txhawb lipolysis thiab hepatic qabzib tso zis los ntawm txoj kev glucagon, exerting ntau yam metabolic cov txiaj ntsig ntawm cov piam thaj txo qis, poob phaus, tswj lipid thiab txhim kho hepatic steatosis. Hloov kho nrog fatty acid side chains, nws tau zoo heev txhim kho peptidase tsis kam thiab ua kom ntev hauv vivo ib nrab-lub neej, txhawb kev ncua sijhawm ntev. Hauv cov tsiaj rog rog thiab hom 2 mob ntshav qab zib hom 2, nws koob tshuaj -nyob ntawm qhov hnyav ntawm lub cev, txhim kho glycemic tswj thiab insulin rhiab heev, nrog rau kev poob phaus zoo dua rau tib lub hom phiaj GLP-1 agonists. Nws yog cov cuab yeej tseem ceeb peptide rau kev tshawb fawb txog kev rog rog, ntshav qab zib hom 2, tsis haus dej cawv steatohepatitis thiab metabolic peptide tshuaj txhim kho. | Kev tshawb fawb txog kev rog rog, kev tshawb fawb txog ntshav qab zib hom 2, tsis yog -kev tshawb nrhiav dej cawv steatohepatitis, kev tshawb fawb metabolic syndrome, kev txhim kho tshuaj metabolic peptide | Glucagon-zoo li peptide 1 receptor (GLP-1R); Glucagon receptor (GCGR); cAMP signaling txoj kev |
Cim npe nrov: Suav teb survodutide tfa manufacturers, lwm tus neeg, Hoobkas
